Clinical Trial Detail

NCT ID NCT02164006
Title Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors TG Therapeutics, Inc.
Indications

Hodgkin's lymphoma

Therapies

Umbralisib

Age Groups: adult

No variant requirements are available.